Vanguard Global Advisers
ALXO icon

Vanguard Global Advisers’s ALX Oncology ALXO Stock Holding History

Vanguard Global Advisers’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.1K Buy
43,038
+33,070
+332% +$59.2K ﹤0.01% 2825
2026
Q1 		$20K Buy
+9,968
New +$19K ﹤0.01% 3311

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Global Advisers's ALXO Position: Q2 2026 in Review

Vanguard Global Advisers increased its ALX Oncology (ALXO) stake by 332% in Q2 2026, buying an estimated $59.2K and bringing the position to 43,038 shares worth $89.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2825.

Vanguard Global Advisers first reported a position in ALXO in Q1 2026 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Vanguard Global Advisers held 43,038 shares of ALX Oncology worth $89.1K as of Q2 2026.
  • Vanguard Global Advisers bought 33,070 ALX Oncology shares in Q2 2026, an estimated $59.2K.
  • ALX Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2825 holding.
  • Vanguard Global Advisers first reported a position in ALX Oncology in Q1 2026 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.